{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"8"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"18"}],"title":"Progressive Disease"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"title":"Not Evaluable"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"description":"using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)","groups":[{"description":"Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).\n\nNivolumab: nivolumab 3 mg/kg every 2 weeks\n\nIpilimumab: ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)","id":"OG000","title":"R/M Adenoid Cystic Carcinoma (ACC)"},{"description":"Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).\n\nNivolumab: nivolumab 3 mg/kg every 2 weeks\n\nIpilimumab: ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)","id":"OG001","title":"R/M SGC of Any Histology, Except ACC (Non ACC)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"2 years","title":"Best Overall Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}